Results 161 to 170 of about 8,451 (175)

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Lancet, The, 2019
Stefan Kasper, Hans-Georg Kopp, Georg Martin Haag   +2 more
exaly  

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Lancet, The, 2019
Luis Paz-Ares, Katsuyuki Hotta, Oleksandr Voitko   +2 more
exaly  

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Edward F Mckone, Damian G Downey, Eva Van Braeckel   +2 more
exaly  

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Lancet, The, 2023
exaly  

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine, 2020
, Shukui Qin, Masafumi Ikeda
exaly  

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Lancet, The, 2011
Colin Baigent, Martin J Landray, Jonathan R Emberson   +2 more
exaly  

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Lancet, The, 2019
Brian I Rini, Thomas Powles, Michael B Atkins   +2 more
exaly  

Essential tremor: “Plus” or “Minus”. Perhaps now is the time to adopt the term “the essential tremors”

Parkinsonism & Related Disorders, 2018
openaire   +2 more sources

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lancet, The, 2013
Dieter Hoelzer
exaly  

PHONE COUNSELING PLUS MEDICATION HELP EVEN HEAVY SMOKERS QUIT

Ca-A Cancer Journal for Clinicians, 2006
exaly